

AMENDMENTS

Please amend the subject application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

1. (Withdrawn) A method for the treatment of cancer comprising administering to a patient in need thereof an immunogenic composition capable of inducing active immunity against at least one angiogenesis-related antigen.
2. (Withdrawn) The method according to claim 1, wherein said immunogenic composition comprises an angiogenesis-related antigenic polypeptide.
3. (Withdrawn) The method according to claim 1, wherein said immunogenic composition comprises a nucleic acid encoding an angiogenesis-related antigenic polypeptide.
4. (Withdrawn) The method according to claim 1, wherein said immunogenic composition comprises a plurality of antigen presenting cells presenting at least one angiogenesis-related antigen on the surface.
5. (Withdrawn) The method of claim 4, wherein said antigen presenting cells are pulsed with at least one angiogenesis-related antigen peptide.
6. (Withdrawn) The method of claim 4, wherein said antigen presenting cells are transfected with mRNA encoding at least one angiogenesis related antigen.
7. (Withdrawn) The method of claim 4, wherein said antigen presenting cells are dendritic cells.

8. (Withdrawn) The method of claim 1, wherein said angiogenesis related antigen is selected from the group consisting of Id1, Id3, VEGF, VEGFR-2, angiopoietin and Tie-2.

9. (Withdrawn) The method of claim 6, wherein said antigen presenting cells are further transfected with mRNA encoding at least one tumor antigen.

10. (Currently Amended) A composition for the treatment or prevention of cancer comprising:

a) antigen presenting cells presenting at least one defined angiogenesis-related antigen; and

b) antigen presenting cells presenting at least one tumor antigen.

11. (Original) The composition of claim 10, wherein said angiogenesis-related antigen is selected from the group consisting of Id1, Id3, VEGF, VEGFR-2, angiopoietin and Tie-2.

12. (Currently Amended) The composition of claim 10, wherein said antigen presenting cells of a) and b) are dendritic cells.

13. (Currently Amended) The composition of claim 10, wherein said antigen presenting cells of a) are transfected with mRNA encoding at least one defined angiogenesis-related antigen.

14. (Currently Amended) The composition of claim 10, wherein said the same antigen presenting cells also present both said defined angiogenesis-related antigen(s) and said at least one tumor antigen antigen(s).

15. (Currently Amended) The composition of claim [[14]] 10, wherein said antigen presenting cells of b) are transfected with mRNA encoding at least one tumor antigen.

16. (Withdrawn) A method of treating cancer comprising the steps of:
(i) obtaining antigen presenting cells from a cancer patient;
(ii) introducing into those cells *in vitro*, mRNA encoding an angiogenesis-related antigen and mRNA encoding a tumor antigen, thereby producing transfected antigen presenting cells; and
(iii) administering said transfected antigen presenting cells to said patient.

17. (Withdrawn) A method of treating cancer comprising the steps of:
(i) obtaining antigen presenting cells from a cancer patient;
(ii) transfecting the antigen presenting cells *in vitro*, with mRNA encoding an angiogenesis-related antigen and mRNA encoding a tumor antigen;
(iii) contacting the transfected antigen presenting cells of step ii with T-lymphocytes to generate immune cells; and
(iv) administering the immune cells to said cancer patient.

18. (Withdrawn) The method according to claim 2 wherein said immunogenic composition further comprises a tumor antigen.

Please add the following new claims:

19. (New) The composition of claim 10, wherein the antigen presenting cells of b) present a mixture of tumor antigens.

20. (New) The composition of claim 10, wherein the antigen presenting cells of b) present one tumor antigen.

21. (New) The composition of claim 20, wherein the one tumor antigen is telomerase reverse transcriptase (TERT).

22. (New) The composition of claim 20, wherein the one tumor antigen is tyrosinase-related protein (TRP)-2.

23. (New) An immunogenic composition comprising antigen presenting cells that have been simultaneously or sequentially transfected with both of the following:

a) a nucleic acid preparation encoding at least one angiogenesis-related antigen; and
b) a separate nucleic acid preparation encoding at least one tumor antigen; wherein the composition elicits an immune response against both said angiogenesis related antigen(s) and said tumor antigen(s).

24. (New) The composition of claim 23, wherein said at least one angiogenesis-related antigen is selected from Id1, Id3, VEGF, VEGFR-2, angiopoietin, and Tie-2.

25. (New) The composition of claim 23, wherein the antigen presenting cells have been transfected so as to express a mixture of tumor antigens.

26. (New) The composition of claim 23, wherein the antigen presenting cells have been transfected so as to express isolated tumor antigen.

27. (New) The composition of claim 23, wherein the antigen presenting cells have been transfected so as to express one tumor antigen.

28. (New) The composition of claim 23, wherein the antigen presenting cells have been transfected so as to express TERT or TRP 2.

29. (New) The composition of claim 23, wherein said nucleic acid preparations were combined before transfection into the cells.

30. (New) A population of dendritic cells that have been simultaneously transfected with both of the following:

a) a nucleic acid preparation encoding at least one angiogenesis-related antigen; and

b) a separate nucleic acid preparation encoding at least one tumor antigen.

31. (New) The dendritic cell of claim 30, which have been transfected with an mRNA preparation encoding a single angiogenesis-related antigen.

32. (New) The dendritic cells of claim 30, wherein said at least one angiogenesis-related antigen is VEGF or VEGFR-2.

33. (New) The dendritic cells of claim 30, which have been transfected with total tumor mRNA.

34. (New) The dendritic cells of claim 30, which have been transected with an mRNA preparation encoding one tumor antigen.

Serial No.: 10/613,262

35. (New) The dendritic cells of claim 30, which have been transected with mRNA encoding TERT.